A Phase 4 interventional study of Metformin and Sitagliptin in Type 2 Diabetes Mellitus, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2018-08-21.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies testing acarbose in Diabetes Mellitus, Type 2 — none open to participants now, none under way, none of them phase 3. Acarbose · Diabetes Mellitus, Type 2.
Among the 30 studies testing acarbose in Diabetes Mellitus, Type 2, this one is the 2nd largest by enrollment of the 29 interventional ones that give a count, is one of 5 that started in 2012, is one of 15 in phase 4, and was the 15th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →None of the 30 studies testing acarbose in Diabetes Mellitus, Type 2 is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →
Acarbose: first FDA approval 1995 (PRECOSE). What it is approved for, and how studies give it, is on its page →
Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
First in 1998; this study’s year is marked. 5 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 5,570 is above the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 100 across the 29 interventional studies. Of the 22 that completed or were terminated, 3 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 30 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc: none open now, none under way, none of them phase 3. Of 181 finished, 150 (83%) have results posted.
Among the 181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc, this one is the 3rd largest by enrollment of the 170 interventional ones that give a count, is one of 20 that started in 2012, is one of 6 in phase 4, and was the 142nd registered.
Merck & Co., Inc’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 30 studies testing acarbose in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 181 in Diabetes Mellitus, Type 2:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To assess the effect of adding acarbose or repaglinide or gliclazide to sitagliptin plus metformin, compared to adding glimepiride, on glycemic improvements in Type 2 Diabetes Mellitus (T2DM) participants who require the addition of a third oral anti-hyperglycemic agent (OAHA) according to China Guideline for Type 2 Diabetes. The three co-primary hypotheses are that after 24 weeks of treatment in phase 2, the mean change from baseline in hemoglobin A1c (A1c) in participants receiving either (1)acarbose or (2)repaglinide or (3)gliclazide added to sitagliptin and metformin combination is non-inferior to that of participants receiving glimepiride added to sitagliptin and metformin combination. The study would be declared successful if at least one of the three primary hypotheses was met.
Participants coming on study will be stabilized to a standardized metformin dose: this may take about 10 weeks, and then combination therapy with metformin + sitagliptin will begin during Phase 1 (Week 0 through Week 20). If a participant has already been on a stabilized metformin dose, they will start immediately on combination therapy with metformin + sitagliptin for 20 weeks (Phase 1).
In Phase 2, participants who have failed to achieve adequate glycemic control (A1c ≥ 7% and ≤ 10% at Week 16 and fasting finger stick glucose ≥130 mg/dL and ≤280 mg/dL at Week 20) will be randomized to receive add-on therapy with glimepiride, repaglinide, acarbose, or gliclazide for 24 weeks (Week 20 through Week 44).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
During Phase 2, participants receive up to 6 mg glimepiride daily as an add-on to metformin + sitagliptin combination therapy for 24 weeks (Week 20 through Week 44).
Drug: Metformin · Drug: Sitagliptin · Drug: Glimepiride
During Phase 2, participants receive up to 16 mg repaglinide daily as an add-on to metformin + sitagliptin combination therapy for 24 weeks (Week 20 through Week 44).
Drug: Metformin · Drug: Sitagliptin · Drug: Repaglinide
During Phase 2, participants receive 50-100 mg acarbose three times daily as an add-on to metformin + sitagliptin combination therapy for 24 weeks (Week 20 through Week 44).
Drug: Metformin · Drug: Sitagliptin · Drug: Acarbose
During Phase 2, participants receive 30-120 mg gliclazide daily as an add-on to metformin + sitagliptin combination therapy for 24 weeks (Week 20 through Week 44).
Drug: Metformin · Drug: Sitagliptin · Drug: Gliclazide
Metformin, 500 mg or 850 mg oral tablets, twice or three times a day (BID or TID) for a total dose of at least 1500 mg daily; administered with food.
Also known as: Fortamet®, Glucophage®, Glucophage® XR, Glumetza®, Riomet®, Metgluco®, Glycoran®
Sitagliptin, 100 mg oral tablet, once daily (QD); administered with or without food
Also known as: Januvia®, Tesavel®, Xelevia®, Ristaben®
Acarbose, 50 mg oral tablets, TID (150 mg total daily dose); administered with the first bite of each main meal.
Also known as: Precose®, Glucobay™
Repaglinide, 0.5 mg and/or 1 mg oral tablets, TID (up to 16 mg daily); administered within 30 minutes of each meal.
Also known as: Prandin®, Fulaidi™
Glimepiride, 1 mg and/or 2 mg oral tablets, QD (up to 6 mg daily); administered before the first main meal of the day
Also known as: Amaryl®, Glimy
Gliclazide, 30 mg oral tablets, QD or BID (30 mg to 120 mg total daily dose); administered with meal.
Also known as: Diamicron MR™
Change From Phase 2 Baseline to Week 44 in Hemoglobin A1c (HbA1c) Levels (Phase 2)
HbA1c is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). Change from baseline reflects the Week 44 A1C minus baseline A1C. Baseline is defined as Visit 6/Week 20. If this measurement was unavailable, the Week 16 value was used. Change from baseline was based on the constrained longitudinal data analysis (cLDA) model including all available measurements from baseline through the last visit. The terms in the cLDA model include treatment, time in weeks (categorical), regions, and treatment-by-time interaction.
Time frame: Phase 2 Baseline (Week 20) and Week 44
Change From Phase 2 Baseline to Week 44 in Participant Body Weight (Phase 2)
Change from baseline in body weight in Phase 2 was reported. Change from baseline reflects the Week 44 body weight minus baseline body weight. Baseline is defined as Visit 6/Week 20. If this measurement was unavailable, the Week 16 value was used.
Time frame: Phase 2 Baseline (Week 20), Week 44
Percentage of Participants With Hypoglycemia Events (Phase 2)
Hypoglycemia events represent epidsodes symptomatic of hypoglycemia (e.g., weakness, dizziness, shakiness, increased sweating, palpitations, or confusion) and/or finger stick glucose values of ≤70 mg/dL (3.9 mmol/L). The percentage of participants with hypoglycemia events was reported.
Time frame: From Week 20 through Week 44
Percentage of Participants With a Gastrointestinal (GI) AE of Nausea (Phase 2)
The percentage of participants with a GI AE of "nausea" was reported.
Time frame: From Week 20 through Week 44
Percentage of Participants With a GI AE of Vomiting (Phase 2)
The percentage of participants with a GI AE of "vomiting" was reported.
Time frame: From Week 20 through Week 44
Percentage of Participants With a GI AE of Diarrhea (Phase 2)
The percentage of participants with a GI AE of "diarrhea" was reported.
Time frame: From Week 20 through Week 44
Percentage of Participants With a GI AE of Abdominal Pain (Phase 2)
The percentage of participants with a GI AE of "abdominal pain" was reported.
Time frame: From Week 20 through Week 44
Adult Chinese participants (≥18 and ≤75 years of age) with a diagnosis of Type 2 Diabetes Mellitus (T2DM) and inadequate glycemic control were selected to participate in this study.
| Milestone | Phase 1: Sitagliptin + Metformin | Phase 2: Metformin + Sitagliptin + Glimepiride | Phase 2: Metformin + Sitagliptin + Repaglinide | Phase 2: Metformin + Sitagliptin + Acarbose | Phase 2: Metformin + Sitagliptin + Gliclazide |
|---|---|---|---|---|---|
| Started | 5570 | 0 | 0 | 0 | 0 |
| Completed | 4933 | 0 | 0 | 0 | 0 |
| Not completed | 637 | 0 | 0 | 0 | 0 |
| Withdrew: Clinical adverse event | 80 | 0 | 0 | 0 | 0 |
| Withdrew: Death | 2 | 0 | 0 | 0 | 0 |
| Withdrew: Hyperglycemia (lack of efficacy) | 13 | 0 | 0 | 0 | 0 |
| Withdrew: Laboratory adverse event | 16 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 147 | 0 | 0 | 0 | 0 |
| Withdrew: Travel, moving, etc. | 30 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 13 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 118 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 218 | 0 | 0 | 0 | 0 |
| Milestone | Phase 1: Sitagliptin + Metformin | Phase 2: Metformin + Sitagliptin + Glimepiride | Phase 2: Metformin + Sitagliptin + Repaglinide | Phase 2: Metformin + Sitagliptin + Acarbose | Phase 2: Metformin + Sitagliptin + Gliclazide |
|---|---|---|---|---|---|
| Started | 0 | 552 | 550 | 556 | 554 |
| Completed | 0 | 500 | 505 | 508 | 507 |
| Not completed | 0 | 52 | 45 | 48 | 47 |
| Withdrew: Clinical adverse event | 0 | 10 | 10 | 6 | 11 |
| Withdrew: Death | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Hyperglycemia (lack of efficacy) | 0 | 0 | 0 | 0 | 2 |
| Withdrew: Laboratory adverse event | 0 | 1 | 0 | 1 | 1 |
| Withdrew: Lost to follow-up | 0 | 10 | 6 | 9 | 5 |
| Withdrew: Travel, moving, etc. | 0 | 2 | 3 | 3 | 5 |
| Withdrew: Physician decision | 0 | 2 | 0 | 1 | 2 |
| Withdrew: Protocol violation | 0 | 19 | 19 | 13 | 9 |
| Withdrew: Withdrawal by subject | 0 | 8 | 6 | 15 | 12 |
HbA1c is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). Change from baseline reflects the Week 44 A1C minus baseline A1C. Baseline is defined as Visit 6/Week 20. If this measurement was unavailable, the Week 16 value was used. Change from baseline was based on the constrained longitudinal data analysis (cLDA) model including all available measurements from baseline through the last visit. The terms in the cLDA model include treatment, time in weeks (categorical), regions, and treatment-by-time interaction.
| Percent | Phase 2: Metformin + Sitagliptin + Glimepiride | Phase 2: Metformin + Sitagliptin + Repaglinide | Phase 2: Metformin + Sitagliptin + Acarbose | Phase 2: Metformin + Sitagliptin + Gliclazide |
|---|---|---|---|---|
| Change From Phase 2 Baseline to Week 44 in Hemoglobin A1c (HbA1c) Levels (Phase 2) | -0.65 ± 0.84 | -0.62 ± 0.84 | -0.46 ± 0.83 | -0.69 ± 0.90 |
Change from baseline in body weight in Phase 2 was reported. Change from baseline reflects the Week 44 body weight minus baseline body weight. Baseline is defined as Visit 6/Week 20. If this measurement was unavailable, the Week 16 value was used.
| kg | Phase 2: Metformin + Sitagliptin + Glimepiride | Phase 2: Metformin + Sitagliptin + Repaglinide | Phase 2: Metformin + Sitagliptin + Acarbose | Phase 2: Metformin + Sitagliptin + Gliclazide |
|---|---|---|---|---|
| Change From Phase 2 Baseline to Week 44 in Participant Body Weight (Phase 2) | 0.4 ± 2.6 | 0.2 ± 2.5 | -0.9 ± 2.5 | 0.2 ± 2.4 |
Hypoglycemia events represent epidsodes symptomatic of hypoglycemia (e.g., weakness, dizziness, shakiness, increased sweating, palpitations, or confusion) and/or finger stick glucose values of ≤70 mg/dL (3.9 mmol/L). The percentage of participants with hypoglycemia events was reported.
| Percentage of Participants | Phase 2: Metformin + Sitagliptin + Glimepiride | Phase 2: Metformin + Sitagliptin + Repaglinide | Phase 2: Metformin + Sitagliptin + Acarbose | Phase 2: Metformin + Sitagliptin + Gliclazide |
|---|---|---|---|---|
| Percentage of Participants With Hypoglycemia Events (Phase 2) | 8.9 | 6.1 | 0.5 | 3.6 |
The percentage of participants with a GI AE of "nausea" was reported.
| Percentage of Participants | Phase 2: Metformin + Sitagliptin + Glimepiride | Phase 2: Metformin + Sitagliptin + Repaglinide | Phase 2: Metformin + Sitagliptin + Acarbose | Phase 2: Metformin + Sitagliptin + Gliclazide |
|---|---|---|---|---|
| Percentage of Participants With a Gastrointestinal (GI) AE of Nausea (Phase 2) | 0 | 0 | 0.4 | 0.2 |
The percentage of participants with a GI AE of "vomiting" was reported.
| Percentage of Participants | Phase 2: Metformin + Sitagliptin + Glimepiride | Phase 2: Metformin + Sitagliptin + Repaglinide | Phase 2: Metformin + Sitagliptin + Acarbose | Phase 2: Metformin + Sitagliptin + Gliclazide |
|---|---|---|---|---|
| Percentage of Participants With a GI AE of Vomiting (Phase 2) | 0.2 | 0 | 0.2 | 0.2 |
The percentage of participants with a GI AE of "diarrhea" was reported.
| Percentage of Participants | Phase 2: Metformin + Sitagliptin + Glimepiride | Phase 2: Metformin + Sitagliptin + Repaglinide | Phase 2: Metformin + Sitagliptin + Acarbose | Phase 2: Metformin + Sitagliptin + Gliclazide |
|---|---|---|---|---|
| Percentage of Participants With a GI AE of Diarrhea (Phase 2) | 0.5 | 0.4 | 0.4 | 0.9 |
The percentage of participants with a GI AE of "abdominal pain" was reported.
| Percentage of Participants | Phase 2: Metformin + Sitagliptin + Glimepiride | Phase 2: Metformin + Sitagliptin + Repaglinide | Phase 2: Metformin + Sitagliptin + Acarbose | Phase 2: Metformin + Sitagliptin + Gliclazide |
|---|---|---|---|---|
| Percentage of Participants With a GI AE of Abdominal Pain (Phase 2) | 0 | 0 | 0.4 | 0.2 |
Collected over Up to 46 Weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Phase 1: Sitagliptin + Metformin | — | 63/5,527 (1.1%) | 66/5,527 (1.2%) |
| Phase 2: Metformin + Sitagliptin + Acarbose | — | 11/551 (2%) | 3/551 (0.5%) |
| Phase 2: Metformin + Sitagliptin + Repaglinide | — | 9/545 (1.7%) | 33/545 (6.1%) |
| Phase 2: Metformin + Sitagliptin + Gliclazide | — | 10/550 (1.8%) | 20/550 (3.6%) |
| Phase 2: Metformin + Sitagliptin + Glimepiride | — | 8/549 (1.5%) | 48/549 (8.7%) |
| Event | Phase 1: Sitagliptin + Metformin | Phase 2: Metformin + Sitagliptin + Acarbose | Phase 2: Metformin + Sitagliptin + Repaglinide | Phase 2: Metformin + Sitagliptin + Gliclazide | Phase 2: Metformin + Sitagliptin + Glimepiride |
|---|---|---|---|---|---|
| Diabetes Mellitus Inadequate ControlMetabolism and nutrition disorders | 2/5527 | 0/551 | 3/545 | 1/550 | 1/549 |
| AppendicitisInfections and infestations | 1/5527 | 0/551 | 2/545 | 0/550 | 0/549 |
| Acute Myocardial InfarctionCardiac disorders | 0/5527 | 0/551 | 0/545 | 2/550 | 0/549 |
| Cerebral InfarctionNervous system disorders | 2/5527 | 2/551 | 0/545 | 0/550 | 0/549 |
| Intestinal ObstructionGastrointestinal disorders | 0/5527 | 0/551 | 1/545 | 0/550 | 0/549 |
| Pancreatitis AcuteGastrointestinal disorders | 0/5527 | 0/551 | 1/545 | 0/550 | 0/549 |
| Liver AbscessInfections and infestations | 0/5527 | 0/551 | 1/545 | 0/550 | 0/549 |
| FallInjury, poisoning and procedural complications | 0/5527 | 0/551 | 1/545 | 0/550 | 0/549 |
| Myelodysplastic SyndromeNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/5527 | 0/551 | 1/545 | 0/550 | 0/549 |
| Diabetic NeuropathyNervous system disorders | 0/5527 | 0/551 | 1/545 | 0/550 | 1/549 |
| Event | Phase 1: Sitagliptin + Metformin | Phase 2: Metformin + Sitagliptin + Acarbose | Phase 2: Metformin + Sitagliptin + Repaglinide | Phase 2: Metformin + Sitagliptin + Gliclazide | Phase 2: Metformin + Sitagliptin + Glimepiride |
|---|---|---|---|---|---|
| HypoglycemiaMetabolism and nutrition disorders | 66/5527 | 3/551 | 33/545 | 20/550 | 48/549 |
This population includes all participants who enrolled in Phase 1 and were GCP compliant.
| Age, Continuous(Years) | Overall Study |
|---|---|
| Mean | 53.1 ± 9.9 |
| Sex: Female, Male(Participants) | Overall Study |
|---|---|
| Female | 2240 |
| Male | 3295 |
No study locations are listed for this record.
Plan to share: Yes — https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Nov 2012 to primary completion in Apr 2015, 29 months.
Results were first posted in May 2016, 1 year after primary completion.
Of 132 industry-sponsored phase 4 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 28. This study's 29 months is above that.
Counting every sponsor, half of 452 studies reached it within 24 months; a quarter within 13 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Acarbose · Repaglinide · Gliclazide